CALLAN JMB INC.
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $5.7M-12.8% | $6.6M-50.3% | $13.2M |
| Cost of revenue | $3.6M-9.5% | $4.0M-47.0% | $7.6M |
| Gross profit | $2.1M-17.9% | $2.6M-54.6% | $5.6M |
| Selling, general and administrative expenses | $8.6M+77.7% | $4.8M+40.4% | $3.4M |
| Impairment loss on property and equipment | $542K | — | — |
| Loss from operations | -$7.0M-209.2% | -$2.3M-203.3% | $2.2M |
| Interest income | $9K-27.0% | $12K+17.0% | $10K |
| Interest expense | -$3K+50.2% | -$5K+33.9% | -$8K |
| ELOC facility transaction expenses | -$570K | — | — |
| Changes in fair value of derivative liability (see Note 8) | -$371K | — | — |
| Total other income (expenses) | -$935K-14410.3% | $7K+219.4% | $2K |
| Loss before income taxes | -$8.0M-251.3% | -$2.3M-202.9% | $2.2M |
| Provision (benefit) for income taxes | -$3K-111.7% | $25K+10.3% | $23K |
| Net loss | -$8.0M-247.3% | -$2.3M-205.2% | $2.2M |
| Weighted average common shares outstanding - basic | 4.4M+66.5% | 2.6M | — |
| Weighted average common shares outstanding - diluted | 4.4M+66.5% | 2.6M | — |
| Net loss per common share - basic | -$1.82-109.2% | -$0.87 | — |
| Net loss per common share - diluted | -$1.82-109.2% | -$0.87 | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-30 | 2026-06-01 | Dial Gerald | Director | Purchase | 10.0K | $0.76 | $8K | 12.0K | View | |
| 2026-03-20 | 2026-03-26 | Croyle David J | Chief Medical Officer | Purchase | 10.2K | $1.75 | $18K | 800.0K | View | |
| 2026-03-06 | 2026-03-10 | Croyle David J | Chief Medical Officer | Purchase | 14.8K | $1.76 | $26K | 789.8K | View |
Informational purposes only, not investment advice.